Navigation Links
Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
Date:12/6/2007

SAN FRANCISCO, Dec. 6 /PRNewswire/ -- Epiphany Biosciences announced today, the initiation of a Phase 2 clinical trial with valomaciclovir (EPB-348) for the treatment and management of acute infectious mononucleosis. Currently, there are no approved therapeutics for the treatment for this debilitating condition or any other disease caused by the Epstein-Barr virus (EBV)

"Valomaciclovir has shown a broad spectrum of anti-viral activity, including inhibition of viral replication of herpes zoster and EBV," said Fred Volinsky, MD, Chief Executive Officer. "EBV has been implicated in a number of chronic and transplant-related diseases. This initial study in acute mononucleosis will set the stage for broader indications involving EBV as an etiologic agent. We are pleased to be working with the University of Minnesota on this important project".

"EBV is a highly prevalent virus, with up to 95% of middle-aged adults possessing evidence of viral exposure according to CDC surveillance data," stated Brian Murphy, MD, Chief Medical Officer. "Mononucleosis can severely undermine quality-of-life and the acute EBV infection may lead to other long-term medical sequelae. This double-blind, placebo-controlled, clinical trial will examine fluctuations in viral load as influenced by valomaciclovir as well as assess symptom scores."

"Our laboratory has found valomaciclovir to be a very potent anti-viral agent against EBV", reported Dr. Henry H. Balfour, Jr., Professor of Pediatrics and Laboratory Medicine and Pathology at the University of Minnesota, who is principal investigator for the study. "If this proof of concept study is successful, further large scale studies are warranted. We urgently need a solution for this disease that can severely impact the lives of young adults."

The acute mononucleosis study at the University of Minnesota will mark the first of several planned studies of valomaciclovir against EBV related diseases. Comparative anti-EBV
'/>"/>

SOURCE Epiphany Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... -- According to statistics released by the American Society of ... fillers, such as the JUVEDERM ® family of fillers ... between 2013 to 2014, HA filler treatments increased by 8 ... which shows U.S. unit sales of HA dermal fillers were ... "These findings are consistent with what I see every day ...
(Date:3/2/2015)... , March 2, 2015 Cardinal Health today ... a leading global manufacturer of cardiology and endovascular devices, ... net of the present value of tax benefits. The ... of $1.0 billion in new senior unsecured notes and ... to close in the United States ...
(Date:3/2/2015)... and BETHESDA, Md. , March ... company focused on treating and preventing autoimmune diseases, announced ... monoclonal antibody (AMG 714) from Amgen (NASDAQ: ... agreement, Celimmune has the rights to develop, manufacture and ... Japan . Concurrently, Amgen has been granted ...
Breaking Medicine Technology:Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 2Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 3Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 4Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 5Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 6Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 7Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 2Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 3Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 4Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 5Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 6Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 7Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3
(Date:3/2/2015)... March 02, 2015 Éminence Organic Skin ... care, is excited to announce the launch of the ... an effective, time-saving solution for those with combination skin. ... in 1 divided jar to separate the products, consists ... Treatment. The Balancing Moisturizer Duo, also in a divided ...
(Date:3/1/2015)... 02, 2015 To help ... manage their practices compliantly and profitably, MDreferralPRO ... solution. The interoperability between a strategic ... medical practice management system is necessary for ... sustainability. A referral management and development solution ...
(Date:3/1/2015)... 01, 2015 Women’s Excellence is pleased ... terms on their website. There are over 75 terms ... time. , “This gives our patients a better understanding ... terminology that they may not understand. With this resource, our ... mobile optimized) and find terms and phrases that they may not ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Adults who ... insurance rates for term or universal policies can now ... of the best life insurance companies for single adults ... system at http://quotespros.com/life-insurance.html . , The rate plans ... portal are tied to a number of life protection ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Ticket Down is ... in Chicago at Soldier Field. Deadheads have been ... in January. , Grateful Dead was formed 50 years ago ... were together as one until the untimely death of Jerry ... combining different genres including blues, reggae, rock, bluegrass, folk, space ...
Breaking Medicine News(10 mins):Health News:Éminence Organic Skin Care Launches Innovative Collection for Combination Skin 2Health News:Éminence Organic Skin Care Launches Innovative Collection for Combination Skin 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2
... Jan. 27 The Michael J. Fox Foundation ... for seven Parkinson,s drug development projects. The funding ... track of the Foundation,s industry-focused Therapeutics Development ... Therapeutics Development Initiative , the Foundation aims to ...
... dropped regulations overseeing the performance of two common heart ... researchers at Baylor College of Medicine (BCM), Rice University ... online in the journal Health Services Research . ... or CON, require hospitals to obtain approval from a ...
... bone density but short-term use safe, researchers say , , ... heart failure drugs called loop diuretics does not appear to ... study finds, but their effect over the long term is ... as Lasix, Bumex and Demadex, which are commonly prescribed to ...
... Is beauty really in the eye of the,beholder? Does ... Are,males truly the more promiscuous sex? These and other fascinating ... OF SEX,APPEAL, premiering Sunday, February 8 at 9 PM ET ... SCIENCE OF SEX APPEAL delves into our ...
... and even government officials are using the internet ... a report to be published in the ... Lorence of Penn State Center for Technology Assessment, ... growth of the internet as an information source ...
... Honored at Adrian Awards Gala Jan. 26, 2009 in New York ... ... 2009 -- EliteMeetings.com received a Bronze Adrian Award for ... Association International (HSMAI) 52nd annual Adrian Awards Competition. The Adrian Awards ...
Cached Medicine News:Health News:Michael J. Fox Foundation Awards $2.5 Million for Parkinson's Drug Development Projects Led By Academic Investigators 2Health News:Easing regulations does not mean lower quality of cardiac care 2Health News:Some Heart Failure Meds May Raise Fracture Risk in Women 2Health News:Some Heart Failure Meds May Raise Fracture Risk in Women 3Health News:This February Discovery en Espanol Delves Into The Subconscious World of Attraction in 'Science of Sex Appeal' 2Health News:This February Discovery en Espanol Delves Into The Subconscious World of Attraction in 'Science of Sex Appeal' 3Health News:Pharmaceutical disobedience 2Health News:Elitemeetings.com Wins Bronze in HSMAI'S Annual Adrian Awards Competition 2
... OTI's new Spectral system is a combination ... Laser Ophthalmoscope (SLO) system that provides suberb, ... choroidal-retina structure. With the advancements of spectral ... of up to 27,000 A-Scans per second ...
... Arctic Circler uses the same cryoconsole ... AF originating in the pulmonary veins. Arctic ... challenge the traditional palliative-only treatments that rely ... the Arctic Circler catheter has the ability ...
The KMedic Jet Wire Twister is designed to provide fast, smooth and even twisting of soft wire, saving time in the O.R. Now available for the first time in stainless steel. Suitable for the entire ra...
Osteophyte periosteal elevator for bone removing....
Medicine Products: